We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of
these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine …

Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response
rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral …

There are few studies directly comparing the efficacy and safety of telbivudine and entecavir.
The present prospective cohort study aimed to evaluate the long-term efficacy and safety of …

Background & Aims: A previous 4-week trial of telbivudine in patients with chronic hepatitis B
indicated marked antiviral effects with good tolerability, leading to the present 1-year phase …

Background: Because drug-resistant strains of hepatitis B virus (HBV) have developed, and
because serum HBV-DNA levels may rebound in patients who receive treatment with …

The pharmacokinetics of telbivudine were evaluated in adult patients with chronic hepatitis B
virus (HBV) infection following once-daily oral administration at escalating doses of 25, 50 …

Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine
and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and …

This study evaluated the effect of hepatic impairment on the pharmacokinetics of telbivudine,
an investigational nucleoside antiviral for the treatment of chronic hepatitis B virus infection …

Chronic hepatitis B (CHB) patients with higher hepatitis B virus (HBV) load (higher viral load
[HVL], HBV DNA≥ 1× 107 copies/mL) require antiviral therapy, but data for evaluating the …

Background Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a
key therapeutic goal for chronic hepatitis B. Methods In this double-blind, phase 3 trial, 1370 …